The potential therapeutic benefit of resveratrol on Th17/Treg imbalance in immune thrombocytopenic purpura.

[1]  M. Monteiro,et al.  Resveratrol Role in Autoimmune Disease—A Mini-Review , 2017, Nutrients.

[2]  M. Mingot-Castellano,et al.  Sustained Remission in Patients with Primary Immune Thrombocytopenia after Romiplostim Tapering and Discontinuation: A Case Series in Real Life Management in Spain , 2017, Case reports in hematology.

[3]  B. Bonnotte,et al.  Pathogenesis of immune thrombocytopenia. , 2017, Autoimmunity reviews.

[4]  Na Liu,et al.  An increased expression profile of Th9/IL-9 correlated with Th17/IL-17 in patients with immune thrombocytopenia , 2017, Platelets.

[5]  Shuang Liu,et al.  Cytokine changes in response to TPO receptor agonist treatment in primary immune thrombocytopenia , 2017, Cytokine.

[6]  A. Nadeem,et al.  Resveratrol Ameliorates Dysregulation of Th1, Th2, Th17, and T Regulatory Cell-Related Transcription Factor Signaling in a BTBR T + tf/J Mouse Model of Autism , 2017, Molecular Neurobiology.

[7]  V. Bordignon,et al.  Downregulation of proinflammatory cytokines in HTLV-1-infected T cells by Resveratrol , 2016, Journal of Experimental & Clinical Cancer Research.

[8]  B. George,et al.  Long-term outcome following splenectomy for chronic and persistent immune thrombocytopenia (ITP) in adults and children , 2016, Annals of Hematology.

[9]  Liang Zhou.  AHR Function in Lymphocytes: Emerging Concepts. , 2016, Trends in immunology.

[10]  X. Ju,et al.  Indirubin Increases CD4+CD25+Foxp3+ Regulatory T Cells to Prevent Immune Thrombocytopenia in Mice , 2015, PloS one.

[11]  A. Newland,et al.  Current Management of Primary Immune Thrombocytopenia , 2015, Advances in Therapy.

[12]  K. Moudgil,et al.  Involvement of the IL-23/IL-17 axis and the Th17/Treg balance in the pathogenesis and control of autoimmune arthritis. , 2015, Cytokine.

[13]  Qingsheng Li,et al.  Plasma Levels of Interleukin 12 Family Cytokines and Their Relevant Cytokines in Adult Patients with Chronic Immune Thrombocytopenia before and after High-Dose Dexamethasome Treatment , 2015, Medical Principles and Practice.

[14]  K. Pogoda,et al.  The Role of IL-17 and Th17 Lymphocytes in Autoimmune Diseases , 2015, Archivum Immunologiae et Therapiae Experimentalis.

[15]  Jun Yao,et al.  Effect of resveratrol on Treg/Th17 signaling and ulcerative colitis treatment in mice. , 2015, World journal of gastroenterology.

[16]  D. Ma,et al.  Inactivation of Notch signaling reverses the Th17/Treg imbalance in cells from patients with immune thrombocytopenia , 2015, Laboratory Investigation.

[17]  Yan Chen,et al.  The Role of IL-23/Th17 Pathway in Patients with Primary Immune Thrombocytopenia , 2015, PloS one.

[18]  I. Valkova,et al.  RESVERATROL: RECOMMENDING ITS WIDE INCREASE – A PREMATURE DECISION OR NOT? A REVIEW , 2015 .

[19]  G. Perdew,et al.  Aryl hydrocarbon receptor ligands in cancer: friend and foe , 2014, Nature Reviews Cancer.

[20]  T. Kishimoto,et al.  Aryl Hydrocarbon Receptor and Kynurenine: Recent Advances in Autoimmune Disease Research , 2014, Front. Immunol..

[21]  J. Bussel,et al.  Management of thrombocytopenia , 2014, F1000prime reports.

[22]  P. Miossec,et al.  Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. , 2014, Autoimmunity reviews.

[23]  M. El-Shahat,et al.  Alterations in immune cell subsets and their cytokine secretion profile in childhood idiopathic thrombocytopenic purpura (ITP) , 2014, Clinical and experimental immunology.

[24]  D. Kuter.  The biology of thrombopoietin and thrombopoietin receptor agonists , 2013, International Journal of Hematology.

[25]  M. Kuwana,et al.  CD4+CD25+Foxp3+ regulatory T cells in the pathophysiology of immune thrombocytopenia. , 2013, Seminars in hematology.

[26]  Yunfeng Cheng,et al.  The Ratio of Treg/Th17 Cells Correlates with the Disease Activity of Primary Immune Thrombocytopenia , 2012, PloS one.

[27]  P. Imbach.  Treatment of immune thrombocytopenia with intravenous immunoglobulin and insights for other diseases. A historical review. , 2012, Swiss medical weekly.

[28]  O. A. Martins Filho,et al.  The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopenia , 2011, Haematologica.

[29]  P. Pávek,et al.  The function of cytochrome P450 1A1 enzyme (CYP1A1) and aryl hydrocarbon receptor (AhR) in the placenta. , 2011, Current pharmaceutical biotechnology.

[30]  T. Petro.  Regulatory role of resveratrol on Th17 in autoimmune disease. , 2011, International immunopharmacology.

[31]  J. Matthews,et al.  Inhibition of aryl hydrocarbon receptor-dependent transcription by resveratrol or kaempferol is independent of estrogen receptor α expression in human breast cancer cells. , 2010, Cancer letters.

[32]  S. Vesely,et al.  The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports , 2010, American journal of hematology/oncology.

[33]  N. Cooper.  Intravenous immunoglobulin and anti-RhD therapy in the management of immune thrombocytopenia. , 2009, Hematology/oncology clinics of North America.

[34]  Thomas Korn,et al.  IL-17 and Th17 Cells. , 2009, Annual review of immunology.

[35]  J. George,et al.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. , 2009, Blood.

[36]  N. Kerkvliet,et al.  Functional Characterization and Gene Expression Analysis of CD4+CD25+ Regulatory T Cells Generated in Mice Treated with 2,3,7,8-Tetrachlorodibenzo-p-Dioxin1 , 2008, The Journal of Immunology.

[37]  S. Amadori,et al.  Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. , 2008, Blood.

[38]  E. Hauben,et al.  Activation of the aryl hydrocarbon receptor promotes allograft-specific tolerance through direct and dendritic cell-mediated effects on regulatory T cells. , 2008, Blood.

[39]  J. Buer,et al.  The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins , 2008, Nature.

[40]  H. Weiner,et al.  Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor , 2008, Nature.

[41]  L. Horstman,et al.  Antiphospholipid antibodies in immune thrombocytopenic purpura tend to emerge in exacerbation and decline in remission , 2005, British journal of haematology.